US FDA okays Merck's new once-daily HIV pill
The newly approved pill combines 100 mg of doravirine with 0.25 mg of islatravir
The newly approved pill combines 100 mg of doravirine with 0.25 mg of islatravir
The approved product is a generic version of Ravicti, originally developed and marketed by Horizon Therapeutics
The drug is designed to provide temporary relief from cough caused by throat and bronchial irritation
Genome editing holds extraordinary promise for treating previously incurable genetic diseases
At the core of Verida is Spectral Precise Image technology paired with a third-generation Nano-panel Precise dual-layer detector and an AI-based deep learning reconstruction engine
The company stated that it will work closely with the regulator to address the observations within the stipulated timeframe
Zero-observation outcomes strengthen global credibility and accelerate CDMO ambitions
The investigational therapy, ifinatamab deruxtecan, is a potential first-in-class B7-H3 directed DXd antibody drug conjugate discovered by Daiichi Sankyo and jointly developed with Merck
Subscribe To Our Newsletter & Stay Updated